©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
In Vitro Activity of Hepatitis C Virus Protease NS3 Purified from Recombinant Baculovirus-infected Sf9 Cells (*)

(Received for publication, August 7, 1995; and in revised form, November 18, 1995)

Christian Steinkühler Licia Tomei Raffaele De Francesco (§)

From the Istituto di Ricerche di Biologia Molecolare ``P. Angeletti'' Pomezia, 00040 Rome, Italy

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

A recombinant Baculovirus expression system was used for the production of a 20-kDa protein encompassing the hepatitis C virus NS3 protease domain. The protein was purified to apparent homogeneity after detergent extraction of cell homogenates. It was shown to be a monomer in solution and to cleave the in vitro translated precursor proteins NS4A-NS4B and NS5A-NS5B, but not the NS4B-NS5A or the NS3-NS4A precursors. The enzyme also cleaved a 20-mer peptide corresponding to the NS4A-NS4B junction with k/K = 174 M s. Peptides harboring NS4A sequences comprising amino acids 21-54 (Pep4A) and 21-34 (Pep4A) were found to induce an up to 2.8-fold acceleration of cleavage. Kinetic analysis revealed that this acceleration was due to an increase in k, whereas no significant effect on K could be detected. Pep4A was also an absolute requirement for cleavage of in vitro translated NS4B-NS5A by the purified protease. From these data we conclude that: (i) the purified protease domain shows substrate specificity and cleavage requirements similar to those previously reported on the basis of transfection experiments, (ii) activation of the purified protease by the NS4A co-factor can be mimicked by synthetic peptide analogs, and (iii) a central hydrophobic region of NS4A with a minimum core of 14 amino acids is responsible for the interaction with NS3.


INTRODUCTION

The hepatitis C virus (HCV) (^1)is the causative agent of parenterally transmitted non-A non-B hepatitis(1, 2) . The virus contains a positive stranded RNA genome of 9.5 kilobases with a single open reading frame encoding for a polyprotein of 3010-3033 amino acids(3, 4, 5, 6) . Upon translation this polyprotein is proteolytically processed into nine different polypeptides, which are encoded as follows on the viral RNA: 5`-C-E1-E2-NS2-NS3-NS4A-NS4B-NS5A-NS5B-3`.

The mature structural proteins, C (the nucleocapsid protein), E1, and E2 (the two envelope proteins) have been shown to arise via proteolytic processing by host signal peptidases(7, 8) .

Conversely, generation of the mature nonstructural proteins NS2 through NS5B relies on the activities of virally encoded proteases. Thus, cleavage at the NS2-NS3 junction is accomplished by an as yet poorly characterized protease encoded between NS2 and NS3(9, 10) . We (11) and others (12, 13, 14, 15, 16) have shown all subsequent cleavages downstream of NS3, i.e. at the NS3-NS4A, NS4A-NS4B, NS4B-NS5A, and NS5A-NS5B junctions, to be catalyzed by a serine protease contained within the N-terminal region of NS3.

Characterization of cleavage events has shown that there are kinetic differences in processing of the single junctions. Thus, while processing between NS3 and NS4A is an intramolecular event, cleavage at all other sites has been demonstrated to occur in trans.

Homology modeling of the active site of the NS3 protease has permitted us to predict the preference for a cysteine residue at the P1 (according to the nomenclature introduced by Schechter and Berger(17) ) positions of the substrates(18) . Subsequent sequencing of the single cleavage sites has partially confirmed our predictions and yielded the consensus sequence D/E-X-X-X-X-C-A/S for all trans cleavage sites, with X being any amino acid and the scissile bond being located between C and A or S(12, 18) . Notably, the intramolecular cleavage site between NS3 and NS4A differs from this consensus having a threonine residue in the P1 position.

NS3 is necessary, but not sufficient, for cleavage events within the polyprotein between NS3 and NS5B. As a matter of fact we (19) and others (20) have shown the NS3 protease to be a heterodimeric protein in vivo consisting of both NS3 and NS4A. Truncation experiments have mapped the N terminus of NS3 as the domain responsible for interaction with NS4A(21) . The same region has been recently shown to be sufficient for NS4A binding when fused to a heterologous protein (22) . In transfection experiments the interaction between NS3 and NS4A accelerates basal cleavage rates at the NS4A-NS4B and NS5A-NS5B junctions, whereas no cleavage occurs at the NS4B-NS5A site in the absence of NS4A, making the correct processing of the NS4B-NS5A precursor completely dependent upon the presence of NS4A(19, 20) .

NS4A is a 54-residue protein. Deletion mutagenesis experiments have demonstrated that a central region of NS4A spanning from residue 22 through 34 is sufficient for co-factor activity(23) .

Neither the mechanism of protease activation by NS4A nor the reasons for the different cleavage kinetics are known. Mechanistic investigations are hampered by difficulties in obtaining sufficient amounts of pure, active protease. As a matter of fact, the NS3 protein is a multidomain protein of 70 kDa, which, in addition to the protease domain at the N terminus, contains a putative RNA-helicase at its C terminus. C- and N-terminal truncation experiments (21) have demonstrated that a 20-kDa N-terminal fragment of NS3 is capable of performing all cleavages in in vitro translation and in transfection experiments with an efficiency indistinguishable from that of the wild type enzyme, retaining its ability to interact with NS4A (21) .

In this paper, we report the expression of this NS3 protease domain in a Baculovirus expression system, the purification and the characterization of the in vitro activity of this protein. We further show that peptides encompassing sequences of NS4A are capable of activating the purified protease and demonstrate that a minimum central core region of 14 amino acids in fact mediates the interaction of NS4A with NS3.


MATERIALS AND METHODS

Construction of Recombinant Baculovirus

To construct the plasmid pBacPro, a DNA fragment spanning the NS3 protein from residue 1038 to residue 1226 of the HCV polyprotein was obtained by polymerase chain reaction using appropriate oligonucleotides, which insert an ATG codon at the 5`-end and a TAG stop codon at the 3`-end of the sequence. The fragment has been inserted into the BamHI site of the pBlueBacIII vector which was previously filled with the Klenow enzyme. The cloned fragment was completely sequenced in order to exclude the introduction of mutations by polymerase chain reaction.

The pBacNS5AB plasmid was obtained inserting into the BamHI site of the pBlueBacIII vector a DNA fragment encoding HVC polyprotein from amino acids 1973 to 3011. Linearized AcNPV DNA (Invitrogen) was co-transfected with each plasmid into the insect cell line Sf9 to obtain recombinant Baculovirus vBacPro and vBacNS5AB expressing the NS3 protease domain or the NS5AB polyprotein, respectively. Viral plaques were isolated and amplified according to the protocol recommended by the manufacturer.

Radiolabeling and Immunoprecipitations

Sf9 cells seeded at a density of 2 times 10^6/6-cm plate were co-infected with the recombinant Baculovirus vBacPro and vBacNS5AB at a multiplicity of 5 plaque-forming units/cell. At 24 h post-infection the medium was replaced with Grace's medium lacking methionine (Life Technologies, Inc.), and the cells were starved for 1 h at 27 °C. Cells were then radiolabeled for 4 h with 280 µCi of S-ProMix (Amersham Corp.) in Grace's medium lacking methionine and supplemented with 2% dialyzed fetal calf serum. Cells were harvested and lysed for immunoprecipitation in 150 ml of IPB (20 mM Tris, pH 8.0, 150 mM NaCl, 1% Triton). Immunoprecipitations on denatured extracts were performed as described (11) .

Subcellular Fractionation and Flotation of Membrane-associated Proteins on Discontinuous Sucrose Gradients

Sf9 cells (approximately 2 times 10^8) were infected with vBacPro and collected 40-h post-infection. The cell pellets were resuspended in 0.5 ml of buffer A (20 mM Hepes, pH 8.0, 1.5 mM MgCl(2), 0.5 mM EDTA, 3 mM DTT). Cells were incubated 5 min on ice and homogenized with 30 strokes of a tight-fitting pestle using a Dounce homogenizer. The cell homogenate was adjusted to isotonic conditions by addition of 83 µl of buffer B (buffer A + 480 mM KCl, 1.5 M sucrose) and homogenized with 30 additional strokes. The homogenate was centrifuged for 4 min at 1000 times g. The post-nuclear fraction (0.5 ml) was loaded onto a 0.5-ml 35% sucrose cushion (buffer A + 80 mM KCl, 1 M sucrose) and centrifuged for 2 h at 100,000 times g. The pellet, corresponding to the microsomal fraction, was resuspended in 250 µl of buffer D (50 mM triethanolamine, pH 7.5, 250 mM sucrose, 3 mM DTT). 50 µl were diluted with 0.9 ml of 2.3 M sucrose (80%) in TKM buffer (20 mM Tris, pH 7.5, 150 mM KCl, 2 mM MgCl(2)) and the layered under a discontinuous sucrose gradient consisting of 1 ml of 1.9 M sucrose (65%), 1 ml of 1.6 M sucrose, 1 ml of 1.3 M sucrose, 0.8 ml of 1.1 M sucrose, and 0.2 ml of TKM buffer. The gradient was centrifuged for 16 h at 100,000 times g, after which 300-µl fractions were collected. The proteins in each fraction were trichloroacetic acid-precipitated and analyzed by immunoblotting using polyclonal anti-NS3 antisera.

Cell Culture and Protein Purification

Sf9 cells were grown at 27 °C in supplemented Grace's insect medium containing 10% (v/v) heat-inactivated fetal bovine serum (Life Technologies, Inc.). 10^9 cells grown to a density of 2 times 10^6 cells/ml were harvested by centrifugation, resuspended in fresh medium at a density of 10^7 cells/ml, and infected with P3 recombinant Baculovirus stocks at a multiplicity of infection of 5-10. One hour post-infection cells were transferred into a spinner flask, and fresh medium was added to reach a final cell density of 10^6 cells/ml. Cells were grown for an additional 72 h at 22 °C with constant stirring at 80 rpm and collected by centrifugation. After extensive washing with PBS (20 mM sodium phosphate, pH 7.4, 140 mM NaCl), the cell pellet was resuspended in lysis buffer containing: 25 mM sodium phosphate, pH 6.5, 20% glycerol, 0.5% CHAPS, 10 mM DTT, 1 mM EDTA, and cells were disrupted by sonication on ice (four 30-s strokes at 18-watt output with 30-s intervals, using a Branson 250 Sonifer). Cell disruption (routinely >90%) was checked by determination of the number of remaining intact cells using a Neubauer chamber. The homogenate thus obtained was clarified by centrifugation at 120,000 times g for 1 h, and the resulting supernatant was loaded on a HR 26/10 S-Sepharose column (Pharmacia Biotech Inc.) equilibrated with 25 mM sodium phosphate buffer, pH 6.5, 10% glycerol, 2 mM DTT, 1 mM EDTA, 0.1% CHAPS, operating at a flow rate of 2 ml/min. After washing with 2 column volumes of equilibration buffer, the protease was eluted with a linear 0-1 M NaCl gradient. In this and in the subsequent chromatographic steps the presence of the NS3 protease in the single fractions was detected by silver staining as well as by Western blots of precast 12.5% polyacrylamide minigels run under denaturing conditions (PhastSystem, Pharmacia). The pooled, NS3-containing fractions were concentrated to 3 ml using an Amicon stirred ultrafiltration cell equipped with a YM 10 membrane and chromatographed on a HR 26/60 Superdex 75 column (Pharmacia) equilibrated with 50 mM sodium phosphate buffer, pH 7.5, 10% glycerol, 2 mM DTT, 0.1% CHAPS, 1 mM EDTA and operating at 1 ml/min. A final chromatographic step was performed on a HR 5/5 Mono S column equilibrated with 50 mM sodium phosphate buffer, pH 7.5, 10% glycerol, 2 mM DTT, 1 mM EDTA, 0.1% CHAPS operating at 0.5 ml/min. Elution was achieved by applying a 0-0.5 M NaCl gradient. The protein was homogeneous after this step as judged from SDS-PAGE and >90% pure as judged by HPLC performed using a 0.46 times 25-cm reversed phase column (5 µm, 300 Å, C4, Vydac). The protein was stored in aliquots at -80 °C in 40 mM sodium phosphate, pH 7.5, 40% glycerol, 0.1% CHAPS, 2 mM DTT. Protein concentration was estimated from UV spectra by determination of the absorbance at 280 nm: an extinction coefficient of = 18,200 M cm was calculated on the basis of primary sequence data according to published procedures(24) , and concentration of NS3 was determined according to the Lambert Beer law. Alternatively, a modification of the Lowry method (25) with bovine serum albumin as standard was used. The final yield was 0.5 mg of purified protein/liter of cultured cells.

In Vitro Translation of NS3 Substrates

Appropriate DNA fragments derived from HCV-BK (5) cDNA were inserted downstream of the 5`-untranslated region of encephalomyocarditis virus and under the T7 promoter in the pCite-1 vector (Novagen) in the appropriate translational reading frame and followed by a termination codon.

The plasmids pCiteNS3-4A, pCiteNS4AB, pCiteNS4B5A, and pCiteNS5AB expressing, respectively, the HCV proteins NS3-4A from residue 992 to residue 1711, NS4AB from residue 1649 to residue 1964, NS4B5A from residue 1775 to residue 2380, and NS5AB from residue 1965 to residue 3010 were described previously(19) . NS3-NS4ADeltapro was obtained from pCiteNS3-4A by digestion with MscI and SalI, resulting in a transcript expressing residues 1462-1711. NS4BNS5ADeltaC216 was obtained from pCiteNS4B5A by digestion with NheI, resulting in a transcript encompassing residues 1712-2203, while NS5A-NS5BDeltaC51 was obtained by digestion of pCiteNS5AB with BstEI. In vitro transcription was done with T7 RNA polymerase. The transcripts were translated for 1 h at 30 °C in the presence of [S]methionine using an RNA-dependent rabbit reticulocyte lysate (Promega). Aliquots of purified NS3 protease were added to the translated proteins, and the mixture was incubated for up to 2 h at 22 °C. Cleavage of labeled precursors was assessed by SDS-PAGE on 12.5% gels. Control experiments were included to verify the identity of precursors and cleavage products by immunoprecipitation using specific antisera as described previously(11) . Data were analyzed on a PhosphorImager and quantified by volumetric integration using ImageQuant software.

Inhibition Studies

S-Labeled NS5ABDeltaC51 was produced by in vitro translation as described above. After 1 h at 30 °C, translation was stopped by addition of 2.5 mM cycloheximide. 1.9 µM protease in 50 mM sodium phosphate buffer, pH 7.5, 50% glycerol, 2% CHAPS, 2 mM DTT were preincubated with different protease inhibitors at 22 °C for 1 h, and 5 µl of these solutions were added to 15 µl of labeled substrate. After 2 h at 22 °C the reaction was stopped by addition of SDS sample buffer(26) . Samples were run on a 12% SDS-PAGE, and bands were visualized by autoradiography.

Peptides and HPLC Assays

Peptides were synthesized by solid phase synthesis based on Fmoc chemistry. After cleavage and deprotection the crude peptides were purified by HPLC to >98% purity. Identity of peptides was checked by mass spectrometry. Concentration of stock solutions of peptides, prepared in Me(2)SO and kept at -80 °C until use, was determined by quantitative amino acid analysis performed on HCl-hydrolyzed samples.

The following peptides were used: Pep4AB, Fmoc-Y-Q-E-F-D-E-M-E-E-C-A-S-H-L-P-Y-I-E-Q-G; Pep4A, G-S-V-V-I-V-G-R-I-I-L-S-G-R-P-A-I-V-P-D-R-E-L-L-Y-Q-E-F-D-E-M-E-E-Abu; Pep4A, G-R-P-A-I-V-P-D-R-E-L-L-Y-Q-E-F-D-E-M-E-E-Abu; Pep4A, G-S-V-V-I-V-G-R-I-I-L-S-G-R with Abu = amino butyric acid substituting the cysteine residue present in the original sequence.

Cleavage assays were performed using 300 nM to 1.6 µM enzyme in 30 µl of 50 mM Tris, pH 7.5, 50% glycerol, 2% CHAPS, 30 mM DTT, and appropriate amounts of substrate and/or NS4A-peptide, such that the final concentration of Me(2)SO did not exceed 10%. This Me(2)SO concentration was shown not to affect enzyme activity. After incubation for variable time intervals at 22 °C, the reaction was stopped by addition of 70 µl of H(2)O containing 0.1% trifluoroacetic acid. pH dependence experiments were carried out using the following buffers: pH 6.0-7.5, sodium phosphate; pH 7.5-9.0, Tris; pH 9.0-10.5, sodium borate. At overlapping pH values activity was determined with two different buffer systems and shown not to be affected by buffer composition. Ionic strenghth was kept constant at 20 mM.

Cleavage of peptide substrates was assessed by HPLC using a Merck-Hitachi chromatograph equipped with an autosampler. 90-µl samples were injected on a reversed phase HPLC column (C18 Lichrospher, 5 µm, 0.4 times 12.5 cm, Merck) and fragments were separated using a 30-100% acetonitrile gradient at 2%/min. Peak detection was done by monitoring both absorbance at 220 nm and the fluorescence of the N-terminal Fmoc group (excitation, 260 nm; emission, 305 nm). Peptide fragments eluting from the HPLC column were collected and identified by mass spectrometry.

Cleavage products were quantified by integration of chromatograms with respect to the standard peptide Fmoc-Y-Q-E-F-D-E-M-E-E-C. Initial rates of cleavage were determined at <20% substrate conversion. The kinetic parameters of the proteolysis reaction were calculated from least squares fit of initial rates as a function of substrate concentration assuming Michaelis-Menten kinetics with the help of a Grafit or a Kaleidagraph software. k/K(m) values were calculated from initial rates determined at substrate concentrations < K(m).

Binding of Pep4Ato the Purified Protease-To estimate binding parameters of Pep4A to the isolated protease rate enhancements relative to samples containing the protease alone were determined as a function of Pep4A concentration. 200 nM to 3.2 µM Pep4A were added to solutions of 600 nM protease in 50 mM Tris, pH 7.5, 50% glycerol, 2% CHAPS, 30 mM DTT and incubated for 10 min, after which the reaction was started by addition of 60 µM (2 K(m)) substrate Pep4AB. The reaction was stopped at <20% substrate conversion. V was defined as the enhancement of velocity of substrate conversion at a given concentration of Pep4A, and V(max) as the velocity enhancement at Pep4A-saturation. The enzyme-bound Pep4A at a given V can then be calculated from , assuming a 1:1 stoichiometry of the NS3-Pep4A complex (see ``Results''),

with [E(0)] being the total concentration of protease in the assay. Free and bound species were calculated from total Pep4A concentrations, and binding parameters were obtained from fitting data to a Scatchard plot.


RESULTS

Expression of the NS3 Protease Domain in Recombinant Baculovirus-infected Sf9 Cells

Infection of Sf9 cells with a recombinant Baculovirus resulted in expression of immunoreactive NS3 protein with the expected molecular mass of 23 kDa (Fig. 1A). Time course experiments showed increasing amounts of protein to be expressed up to 72 h post-infection, after which a plateau level was reached (Fig. 1A).


Figure 1: Expression of enzymatically active, membrane bound NS3 protease domain in Sf9 cells. A, Sf9 cells were infected with recombinant Baculovirus as described under ``Materials and Methods.'' 1.3 times 10^6 cells were collected by centrifugation at the indicated time points, lysed in SDS sample buffer, and loaded on a 15% polyacrylamide gel. The protease was visualized by immunoblotting. The migration positions of molecular mass markers are indicated on the left. B, homogenates of Sf9 cells expressing the NS3 protease were prepared in 20 mM HEPES, pH 8.0, 1.5 mM MgCl(2), 0.5 mM EDTA, 3 mM DTT and centrifuged for 1 h at 100,000 times g. Pellet (lane 1) and supernatant (lane 2) were loaded on a 15% polyacrylamide gel followed by an immunoblot using anti-NS3 antibodies. The pellet was subsequently loaded on a 38-65% sucrose gradient in 20 mM Tris, pH 7.5, 150 mM KCl, 2 mM MgCl(2) and centrifuged for 16 h at 100,000 times g. The presence of the protease in the single fractions was monitored by immunoblotting. The triangle indicates increasing sucrose concentration. C, Sf9 cells were co-infected with recombinant Baculoviruses encoding the NS3 protease and the NS5A-NS5B substrate as described under ``Materials and Methods.'' After labeling with S, proteins were immunoprecipitated using anti-NS3 (alpha3), anti-NS5A (alpha5A), or anti-NS5B (alpha5B) antibodies. The immunoprecipitates were loaded on 12% polyacrylamide gels and revealed by autoradiography. The molecular masses were estimated from the migration positions of ^14C-labeled molecular mass markers.



Upon centrifugation at 100,000 times g, the protein was almost quantitatively detectable in the pellet (Fig. 1B, lanes S and P). To discriminate whether this was attributable to formation of protein aggregates or to a partitioning of the protein into cell membranes the pellet was loaded on sucrose gradients (Fig. 1B). During these centrifugation experiments the immunoreactive NS3 protein migrated at low density, demonstrating that the protease was not present under the form of an aggregate and was most likely membrane-bound in Sf9 cells.

To determine whether the protein was also expressed in an enzymatically active form Sf9 cells were co-infected with recombinant Baculovirus encoding the NS5A-NS5B precursor protein. Cells were labeled with [S]methionine, and proteins were immunoprecipitated with anti NS3, anti-NS5A, or anti-NS5B, respectively (Fig. 1C). The appearance of immunoprecipitable polypeptides, migrating at the expected molecular mass positions of mature NS5A and NS5B, indicated the expression of enzymatically active NS3 protease in Sf9 cells (Fig. 1C). In control cells not expressing NS3, on the other hand, only the uncleaved NS5A-NS5B precursor was detectable. These findings prompted us to attempt the purification of the enzyme.

Purification of the NS3 Protease Domain

As a first step toward the purification of the enzyme, we tested the capability of a series of non-ionic and zwitterionic detergents to solubilize the protease. To this purpose, we checked the amount of immunoreactive protein in 120,000 times g supernatants of detergent-treated cell extracts. Activity of the solubilized enzyme was measured by assaying the cleavage of in vitro translated NS5A-NS5B precursor protein (data not shown). In this experimental design the detergent CHAPS gave the best results and was therefore used as solubilizing agent as well as added to all buffers during the purification procedure, which is depicted in Fig. 2.


Figure 2: Purification of the NS3 protease domain. Samples deriving from single steps of the purification procedure were loaded on an SDS-12.5% polyacrylamide gel, and bands were visualized by Coomassie staining. Lane 1, molecular mass markers, lane 2, homogenate; lane 3, S-Sepharose pool; lane 4, Superdex-75 pool; lane 5, Mono S pool.



Sf9 cells expressing the NS3 protease were collected 72 h post-infection. After homogenization and centrifugation of the homogenate, the resulting 120,000 times g supernantant was chromatographed on a cation exchange column at pH 6.5, followed by gel filtration chromatography, which simultaneously shifted the pH of the sample to 7.5. A final ion exchange step performed at pH 7.5 removed residual contaminants and yielded a protein that was homogeneous as judged by SDS-PAGE (Fig. 2).

Since molecular mass determination under native and under denaturing conditions yielded the same results (molecular mass of 22.8 kDa as judged from SDS-PAGE, 23.6 kDa as determined by gel filtration, versus 20.1 kDa calculated from the primary sequence), we conclude that the protein was present as a monomeric species in solution.

Activity on in Vitro Translated Substrates

In order to characterize the enzymatic activity of the purified protease, we investigated its ability to cleave the HCV polyprotein precursor. To this purpose S-labeled precursor proteins corresponding to all cleavage sites, i.e. NS3-NS4ADeltapro, NS4A-NS4B, NS4B-NS5ADeltaC216, and NS5A-NS5BDeltaC51 were synthesized by in vitro translation from the appropriate RNAs. In the case of the NS3-NS4A precursor, the protease domain was deleted to avoid self-cleavage, whereas C-terminal deletions were introduced into the NS4B-NS5A and NS5A-NS5B substrates to increase the stability of the precursors. Incubation with purified NS3 protease yielded mature cleavage products in a dose-dependent fashion when either NS4A-NS4B or NS5A-NS5BDeltaC51 were used as substrates (Fig. 3). However, no cleavage products could be detected in the case of the NS3-NS4ADeltapro and NS4B-NS5ADeltaC216 precursors (Fig. 3). This result is in line with previously reported transfection experiments, since cleavage at the NS4B-NS5A site is absolutely dependent upon the presence of NS4A in vivo(19) , and the NS3-NS4A cleavage site was shown to be processed exclusively intramolecularly.


Figure 3: Activity of the purified protease on in vitro translated precursor substrates. NS3-NS4ADeltaPro, NS4A-NS4B, NS4B-NS5ADeltaC216, and NS5A-NS5BDeltaC51 precursor proteins were produced by in vitro translation of the appropriate RNAs in the presence of S-labeled methionine as described under ``Materials and Methods.'' A stock solution containing 11 µM protease was diluted in 50 mM Tris, pH 7.5, 50% glycerol, 2% CHAPS, 30 mM DTT to yield a series of diluted solutions. 5 µl of these dilutions or 5 µl of buffer alone were added to 5 µl of in vitro translated precursor and incubated for 1 h at 30 °C. Final protease concentrations were 0, 203 nM, 610 nM, 1.8 µM, and 5.5 µM. Triangles indicate increasing protease concentration. Each set of experiments was repeated in the presence of 100 µM final concentration of Pep4A (+Pep4A) added from a 2 mM stock solution in Me(2)SO. Reactions were stopped by addition of 15 µl of SDS sample buffer. Samples were run on 12.5% polyacrylamide gels and proteins detected by autoradiography (A) or quantified by densitometry (B: squares, +Pep4A; circles, control). One experiment, representative of five, in which the same trend was consistently observed, is shown.



We wanted to address the question of the role of NS4A in the cleavage efficiency of the protease at different sites and synthesized a 34-mer peptide corresponding to the C terminus of NS4A by solid phase synthesis (Pep4A, see ``Materials and Methods''). We compared the effects of this peptide on the activity of the protease on all precursors. As shown in Fig. 3, Pep4A caused a modest increase of processing at the NS4A-NS4B and NS5A-NS5B sites. The former precursor already contains the NS4A sequences present in Pep4A, which should render the processing at this site less NS4A-dependent. Still no cleavage was detectable at the cis cleavage site, NS3-NS4A, after addition of Pep4A. However, processing was now also detectable at the NS4B-NS5A site, although at higher enzyme concentrations as those required for efficient cleavage of the other two trans sites.

Next, the cleavage of in vitro translated NS5A-NS5BDeltaC51 was used as an assay for testing the inhibitory potential of a series of protease inhibitors on NS3 (Fig. 4). Classical serine protease inhibitors such as PMSF and diisopropyl fluorophosphate, the chymotrypsin inhibitors TPCK as well as aprotinin were effective in inhibiting the NS3 protease. On the other hand, other trypsin, chymotrypsin, cysteine- and metalloproteinase inhibitors were unable to yield significant inhibition of the activity of NS3. Together with previous mutagenesis studies(11) , these findings about its reactivity confirm the identity of the NS3 protease as serine protease.


Figure 4: Effect of protease inhibitors on the processing of the NS5A-NS5BDeltaC51 precursor by the purified protease. Pretranslated radiolabeled NS5A-NS5BDeltaC51 precursor was incubated in the presence of purified NS3 protease and different canonical protease inhibitors as described under ``Materials and Methods.'' Uncleaved precursor and cleavage products were separated on an SDS-12% polyacrylamide gel and visualized by autoradiography. The percentage of cleavage in the presence of added inhibitors was determined by densitometric analysis and data were expressed as percent residual activity with respect to appropriate control samples. Inhibitors and their final concentrations were: DFP, diisopropyl fluorophosphate (1 mM or 10 mM); PMSF, phenylmethylsulfonyl fluoride (1 mM); TPCK, tosylphenylalanyl chloromethyl ketone (1 mM); TLCK, N-p-tosyl-L-lysine chloromethyl ketone (0.5 mM); aprotinin (0.5 mg/ml); chymostatin (0.5 mg/ml); phenanthroline (2 mM); EDTA (2 mM); ZnCl(2) (2 mM); leupeptin (0.5 mg/ml). Data are from one experiment representative of three.



Activity on Peptide Substrates

Our next interest was to find out if the purified protease was able to cleave a synthetic peptide substrate. We excluded the NS3-NS4A site (as a cis cleavage site) and the NS4B-NS5A site (as an absolutely NS4A-dependent site) as possible candidates. Although being the most efficiently cleaved site we excluded also the NS5A-NS5B site due to its hydrophobicity and the problems expected from its two adjacent cysteine residues. As substrate we therefore tested a 20-mer peptide corresponding to the NS4A-NS4B junction (Pep4AB see ``Materials and Methods''). The peptide was used as an Fmoc derivative, since this permitted fluorescence monitoring. Proteolytic cleavage of Pep4AB by the NS3 protease was detectable by HPLC, and occurred as expected after the P1 cysteine residue, since the cleavage products co-migrated with appropriate standards on HPLC. Furthermore, the isolated fragments, when analyzed by mass spectrometry, yielded the expected molecular masses (data not shown).

The cleavage efficiency was highly dependent on the detergent concentration in the assay mix, drastically declining at CHAPS concentrations below the critical micelle concentration value (not shown). The cleavage reaction of Pep4AB had a pH optimum around pH 8.5 and activity titration yielded an apparent pK(a) = 7.0, which are common values for most serine proteases.

We next addressed the question of whether synthetic NS4A analogs were able to increase cleavage efficiency of the purified protease also using Pep4AB as substrate. Furthermore, we wanted to verify that the minimum core region of NS4A is still capable of eliciting full activation of the isolated NS3 protease domain. To this purpose we compared the effects of Pep4A and the truncated peptides Pep4A and Pep4A. As shown in Table 1Pep4A and Pep4A, but not equivalent amounts of Pep4A, were able to stimulate the activity, expressed as k/K(m), of the purified NS3 protease. These data directly confirm the region between amino acids 21 and 34 of NS4A as being responsible for the interaction with NS3 and show that the effect of NS4A is to enhance the efficiency of enzymatic catalysis. We wanted to further dissect the effect of NS4A by determining whether the peptide was increasing the affinity of the enzyme for its substrate or enhancing the catalytic rate. To this purpose substrate titration curves were fitted to the Michaelis-Menten equation and the kinetic parameters were calculated (Table 1). These experiments demonstrate that Pep4A did not significantly affect K(m) values but acted on the rate of catalysis by increasing k values.



To evaluate the affinity of Pep4A for the NS3 protease a Pep4A titration experiment was done monitoring the relative rate enhancement (Fig. 5). Since we found the protease to be still monomeric after complex formation with NS4A (not shown), a 1:1 stoichiometry was assumed for the NS3-Pep4A complex. Based on this assumption an apparent K(d) of 0.22 µM was calculated from a Scatchard plot (Fig. 5).


Figure 5: Binding parameters of Pep4A to the NS3 protease calculated from kinetic data. To 600 nM protease different amounts of Pep4A in Me(2)SO were added and the reaction was started by addition of 60 µM substrate peptide, Pep4AB. After 90-min incubation at 23 °C, the reaction was stopped by addition of 0.1% trifluoroacetic acid. The activity increase, relative to samples incubated with Me(2)SO alone, produced by a given amount of Pep4A4 was plotted against the concentration of Pep4A (A). From these data the amount of bound peptide was calculated (see ``Materials and Methods''), and binding parameters were determined from a Scatchard plot (B). The data obtained were apparent K = 0.22 µM with 0.84 binding sites/enzyme molecule.




DISCUSSION

We here describe the purification of the hepatitis C virus NS3 protease domain from recombinant Baculovirus and the characterization of its enzymatic activity in vitro.

The enzyme was found to be presumably membrane-associated in Sf9 cells, and detergent extraction was necessary to recover appreciable amounts of soluble protein.

The purified enzyme showed a very low specific activity, which is reminiscent of what has been reported for other viral proteases. As a matter of fact, both human cytomegalovirus protease (k/K(m) = 12-400 M s,(27) ) and herpes simplex virus protease (k/K(m) = 17-37 M s(28, 29) ) display cleavage kinetics that are comparable with the parameters we have determined for the HCV protease (k/K(m) = 174 M s). While this manuscript was in preparation, two reports, describing the purification of fusion proteins encompassing both the protease and the helicase domains of the NS3 protein, were published(30, 31) . One report (31) describes the activity on a peptide substrate corresponding to the NS5A-NS5B junction. The kinetic parameters that can be calculated from the published data (k/K(m) = 100 M s) are in good agreement with our own findings.

From transfection experiments the temporal hierarchy of cleavage events of NS3-dependent junctions within the nonstructural region has been determined as being: NS3-NS4A > NS5A-NS5B > NS4A-NS4B NS4B-NS5A, the latter cleavage being completely dependent upon the presence of NS4A. It is likely that this hierarchy reflects physiological requirements of the viral life cycle that are still elusive. Nor do we understand what factors govern the different cleavage kinetics at the single sites. Many open questions probably will have to be addressed by means of kinetic studies on purified proteins. As a first approach in this direction we investigated the activity of the purified NS3 protease domain on precursor proteins bearing all cleavage sites and on a synthetic peptide substrate.

The purified enzyme showed the highest activity on in vitro translated NS5A-NS5B, followed by NS4A-NS4B, while NS4B-NS5A was not detectably cleaved. The latter precursor was cleaved only in the presence of a peptide corresponding to the 34 C-terminal amino acids of NS4A. The same peptide had only very modest effects on the cleavage efficiency at the NS5A-NS5B and NS4A-NS4B sites. Furthermore, no processing was observed in either experimental condition at the NS3-NS4A site. This site, however, is known to be cleaved in cis only, suggesting that steric factors may hinder the cleavage of the NS3-NS4A precursor by the added purified protease.

The activation of NS3 by Pep4A deserves some further comment. It has been shown recently that NS3 and NS4A form an immunoprecipitable complex in transfected cells(21, 22) . On the basis of these data, the activated form of the NS3 protease therefore appears to be a heterodimeric protein consisting of both polypeptides. Several different mechanisms have been suggested to explain the activation of the NS3 protease by the co-factor NS4A(19, 20, 21, 22, 23, 32) , including stabilization, membrane anchoring, alteration of cleavage site specificity, direct contribution to substrate recognition, or induction of structural changes in the substrate binding pocket(s). Although we have some indication of stabilization of the protease toward thermal inactivation upon binding to Pep4A, our kinetic data favor the latter hypothesis. In fact, we have shown the major effect of NS4A to be on the catalytic rate constant k. This rate constant could be increased due to structural rearrangements altering the nucleophilicity of the active site serine residue or affecting transition state binding. It has to be pointed out, however, that these kinetic differences were observed using a peptide derived from an NS4A-independent cleavage site. Comparison of the very small effects of Pep4A on the processing efficiency of the in vitro translated NS4A-NS4B precursor with the absolute Pep4A requirement for NS4B-NS5A precursor processing (Fig. 3) suggests that different mechanisms might account for the effects of NS4A on the processing at the single cleavage sites.

The interaction domain with NS4A has been mapped to the N terminus of NS3(21, 22) . In this work we have addressed the question of what region of NS4A interacts with NS3. A recent report, using a recombinant vaccinia/transfection system comes to the conclusion that a 13-amino acid region spanning residues 22-34 of NS4A is crucial for the interaction with NS3(23) . These findings are confirmed by our observation that deletion of 12 amino acids at the N terminus of Pep4A abolishes its ability to activate NS3, strongly arguing for an involvement of these residues in the interaction with NS3. A further proof of this assumption is given by the fact that the 14-mer peptide Pep4A binds with high affinity to the purified protease and has a potential of activating NS3, which is undistinguishable from the effect observed upon addition of Pep4A. It is interesting to notice that structure predictions of NS4A predict two alpha-helices with a highly hydrophobic region in their middle. This prediction has been partially confirmed by CD spectra of Pep4A(^2)Notably, the residues which are apparently crucial for the interaction with NS3 fall exactly in this region, indicating that a hydrophobic extended structure of NS4A contacts the N-terminal domain of NS3. Proteolytic events mediated by the NS3 protease are likely to be absolute requirements for the generation of an active viral replication apparatus. Sequence alignments point to NS5B as harboring the HCV RNA-dependent RNA-polymerase. As a matter of fact, this protein is generated by an NS3-dependent cleavage. Thus, HCV represents an intriguing example of regulation of both gene expression and replication by crucial proteolysis steps. The elucidation of the role of NS4A in these processes awaits further detailed studies in vitro as well as in vivo. Furthermore, based on these considerations, the enzyme appears as being an attractive candidate target for the development of anti-HCV therapeutics. A deeper understanding of the regulation and the substrate requirements of the protease will help to develop first generation inhibitors.


FOOTNOTES

*
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed. Tel.: 39-6-910-93221; Fax: 39-6-910-93225; defrancesco{at}irbm.it.

(^1)
The abbreviations used are: HCV, hepatitis C virus; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; Fmoc, 9-fluorenylmethyloxycarbonyl; HPLC, high performance liquid chromatography; NS, nonstructural; TPCK, tosylphenylalanyl chloromethyl ketone; DTT, dithiothreitol; PAGE, polyacrylamide gel electrophoresis.

(^2)
C. Steinkühler, L. Tomei, and R. De Francesco, unpublished data.


ACKNOWLEDGEMENTS

We are grateful to Riccardo Cortese for continuous support and encouragement of this work, to Elisabetta Bianchi and Antonello Pessi for peptide synthesis and helpful discussions, and to Piero Pucci for mass spectrometry.


REFERENCES

  1. Choo, Q. L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., and Houghton, M. (1989) Science 244, 359-362 [Medline] [Order article via Infotrieve]
  2. Kuo, G., Choo, Q. L., Alter, H. J., Gitnick, G. L., Redecker, A. G., Purcell, R. H., Myamura, T., Dienstag, J. L., Alter, M. J., Syevens, C. E., Tagtmeyer, G. E., Bonino, F., Colombo, M., Lee, W. S., Kuo, C., Berger, K., Shister, J. R., Overby, L. R., Bradley, D. W., and Houghton, M. (1989) Science 244, 362-364 [Medline] [Order article via Infotrieve]
  3. Choo, Q. L., Richman, K. H., Ham, J. H., Berger, K., Lee, C., Dong, C., Gallegos, C., Coit, D., Medina-Selby, A., Barr, P. J., Weiner, A. J., Bradley, D. W., Kuo, G., and Houghton, M. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 2451-2455 [Abstract]
  4. Kato, M., Hijikata, M., Ootsuyama, Y., Nakagawa, M., Ohkoshi, S., Sugimura, T., and Shimotohno, K. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 9524-9528 [Abstract]
  5. Takamizawa, A., Mori, C., Fuke, I., Manabe, S., Murakami, S., Fujita, J., Onishi, E., Andoh, T., Yoshida, I., and Okayama, H. (1991) J. Virol. 65, 1105-1113 [Medline] [Order article via Infotrieve]
  6. Grakoui, A., Wychowski, C., Lin, C., Feinstone, S. M., and Rice, C. M. (1993) J. Virol. 67, 1385-1395 [Abstract]
  7. Santolini, E., Migliaccio, G., and La Monica, N. (1994) J. Virol. 68, 3631-3641 [Abstract]
  8. Hijikata, M., Kato, N., Ootsuyama, Y., Nagakawa, M., and Shimotohno, K. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 5547-5551 [Abstract]
  9. Hijikata, M., Mizushima, H., Akagi, T., Mori, S., Kakiuchi, N., Kato, N., Tanaka, T., Kimura, K., and Shimotohno, K. (1993) J. Virol. 67, 4665-4675 [Abstract]
  10. Grakoui, A., McCourt, D. W., Wychowski, C., Feinstone, S., and Rice, C. M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10583-10587 [Abstract]
  11. Tomei, L., Failla, C., Santolini, E., De Francesco, R., and LaMonica, N. (1993) J. Virol. 67, 4017-4026 [Abstract]
  12. Grakoui, A., McCourt, D. W., Wychowski, C., Feinstone, S. M., and Rice, C. M. (1993) J. Virol. 67, 2832-2843 [Abstract]
  13. Bartenschlager, R., Ahlborn-Laake, L., Mous, J., and Jacobsen, H. (1993) J. Virol. 67, 3835-3844 [Abstract]
  14. Eckard, M. R., Selby, M., Masiarz, F., Lee, C., Berger, K., Crawford, K., Kuo, C., Kuo, G., Houghton, M., and Choo, Q. L. (1993) Biochem. Biophys. Res. Commun. 192, 399-406 [CrossRef][Medline] [Order article via Infotrieve]
  15. Hijikata, M., Mizushima, H., Tanji, Y., Komoda, Y., Hirowatari, Y., Akagi, T., Kato, N., Kimura, K., and Shimitohno, K. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10773-10777 [Abstract]
  16. Komoda, Y., Hijikata, M., Tanji, Y., Hirowatari, Y., Mizushima, H., Kimura, K., and Shimotohno, K. (1994) Gene (Amst.) 145, 221-226
  17. Schechter, I., and Berger, A. (1967) Biochem. Biophys. Res. Commun. 27, 157-162 [Medline] [Order article via Infotrieve]
  18. Pizzi, E., Tramontano, A., Tomei, L., LaMonica, N., Failla, C., Sardana, M., Wood, T., and DeFrancesco, R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 888-892 [Abstract]
  19. Failla, C., Tomei, L., and DeFrancesco, R. (1994) J. Virol. 68, 3753-3760 [Abstract]
  20. Lin, C., Pragai, B. M., Grakoui, A., Xu, J., and Rice, C. M. (1994) J. Virol. 68, 8147-8157
  21. Failla, C., Tomei, L., and DeFrancesco, R. (1995) J. Virol. 69, 1769-1777 [Abstract]
  22. Satoh, S., Tamji, Y., Hijikata, M., Kimura, K., and Shimotohno, K. (1995) J. Virol. 69, 4255-4260 [Abstract]
  23. Lin, C., Thomson, J. A., and Rice, C. (1995) J. Virol. 69, 4373-4380 [Abstract]
  24. Gill, S., and von Hippel, P. H. (1989) Anal. Biochem. 182, 319-326 [Medline] [Order article via Infotrieve]
  25. Peterson, G. L. (1977) Anal. Biochem. 53, 346-356
  26. Laemmli, U. K. (1970) Nature 227, 680-685 [Medline] [Order article via Infotrieve]
  27. Sardana, V. V., Wolfgang, J. A., Veloski, C. A., Long, W. J., LeGrow, C., Wolanski, B., Emini, E. A., and LaFemina, R. L. (1994) J. Biol. Chem. 269, 14337-14340 [Abstract/Free Full Text]
  28. DiIanni, C. L., Mapelli, L., Drier, D. A., Tsao, J., Natarajan, S., Riexinger, D., Festin, S. M., Bolgar, M., Yamanaka, G., Weinheimer, S. P., Meyers, C. A., Colonno, R. J., and Cordingley, M. G. (1993) J. Biol. Chem. 268, 25449-25454 [Abstract/Free Full Text]
  29. Darke, P. L., Chen, E., Hall, D. L., Sardana, M. K., Veloski, C. A., LaFemina, R. L., Shafer, J. A., and Kuo, L. C. (1994) J. Biol. Chem. 269, 18708-18711 [Abstract/Free Full Text]
  30. D'Souza, E. D. A., Grace, K., Sangar, D. V., Rowlands, D. J., and Clarke, B. E. (1995) J. Gen. Virol. 76, 1729-1736 [Abstract]
  31. Kakiuchi, N., Hijikata, M., Komoda, Y., Tanji, Y., Hirowatari, Y., and Shimotohno, K. (1995) Biochem. Biophys. Res. Commun. 210, 1059-1065 [CrossRef][Medline] [Order article via Infotrieve]
  32. Bartenschlager, R., Ahlborn-Laake, L., Mous, J., and Jacobsen, H. (1994) J. Virol 68, 5045-5055 [Abstract]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.